Prevention of mother to child HIV transmission

Medicina

Volumn 66, Issue 1, 2006, Pages 24-30

  Durán, Adriana S ^b   Ivalo, Silvina A ^b   Hakim, Alejandro ^b   Masciottra, Florencia M ^b   Zlatkes, Rafael ^b   Adissi, Lelia ^b   Neaton, James D ^a   Losso, Marcelo H ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

HIV 1; Pregnancy; Prophylaxis strategies; Safety; Toxicity

Indexed keywords

ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADULT; ANEMIA; ARGENTINA; ARTICLE; CESAREAN SECTION; CLINICAL OBSERVATION; COHORT ANALYSIS; CONGENITAL DISORDER; CONTROLLED STUDY; DRUG ERUPTION; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEUTROPENIA; PREGNANCY; PREVALENCE; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK REDUCTION; SEXUAL TRANSMISSION; THROMBOCYTOPENIA; VAGINAL DELIVERY; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DELIVERY, OBSTETRIC; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES;

EID: 33645112289     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. DeCock K, Fowler MG Mercier E, et al. Prevention of mother-to-child transmission of HIV-1 in resource poor countries: translating research into policy and practice. JAMA 2000, 283: 1175-82.
2. Santmyire B. Vertical transmission of HIV from mother to child in Sub-Saharan Africa: Modes of transmission and methods for prevention. Obstetrical and Gynecological Survey 2001; 56: 306-12.
3. Cooper ER, Charurat M, Burns DN, Blattner W, Hoff R. Trends in antiretroviral therapy and mother-infant transmission of HIV. The Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr 2000; 24: 45-7.
4. Garcia PM, Kalish LA, Pitt J, et al: For the Women and Infants Trans-mission Study Group. Maternal levels of plasma HIV type 1RNA and the risk of perinatal transmission. N Engl J Med 1999; 341: 394-402.
5. American College of Obstetricians and Gynecologists Committee on Obstetrical Practices. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. ACOG Committee Opinion 2000; 234: 1-3.
6. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 Transmission in the United States (online). Available from URL: http:/www.aidsinfo.nih.gov/guidelines/. Accessed June 16, 2003.
7. Nolan ML, Greenberg AE, Fowler MG. A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies. AIDS 2002; 16: 1991-9.
8. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.
9. European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-20.
10. Norma de SIDA en Perinatología. Secretaría de Programas de Salud. Ministerio de Salud y Ambiente. Resolución 105/97, Argentina.
11. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80.
12. Situación epidemiológica del VIH-SIDA en la Ciudad de Buenos Aires. Infosida, 2003; 3: 4-17.
13. Situación epidemiológica del VIH-SIDA en la Ciudad de Buenos Aires. Infosida, 2004; 4: 4-17.
14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0,DCTD,NCI, NIH, DHHS; March 31, 2003 (http:/ctep.cancer.gov), Published June 1, 2003.
15. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Perinatal HIV Prevention Trial Group. Intrapartum Exposure to Nevirapine and subsequent maternal responses to Nevirapine-Based Antiretroviral Therapy. NEJM 2004; 351: 229-40.
16. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIV-1 NET 012). AIDS 2001; 15: 1951-7.
17. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989-31 July 2004. Wilmington, NC: Registry Coordinating Center; 2004. Available at: http://www.registry.com.
18. Red de Centros de Salud Materno-Perinatal Area Metropolitana de Buenos Aires (AMBA) y Sur de la Provincia de Buenos Aires, Argentina. Available at http://www.redperinatalamba.org.ar